Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Dumontet

Showing results (11-20 of 106) with videos related to

Pageof 11
Sort By:
Clinical and Experimental Rheumatology|August 19, 2000
Giant cell arteritis and polymyalgia rheumatica: role of viral infectionsP Duhaut, S Bosshard, C Dumontet
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
Potential interactions between antitubulin agents and temperature: implications for modulation of multidrug resistanceC Dumontet, F Bodin, Y Michal
Cancer Gene Therapy|April 4, 2009
Development of gene therapy in association with clinically used cytotoxic deoxynucleoside analoguesC Hébrard, C Dumontet, L P Jordheim
Current Drug Targets|July 18, 2003
Drug resistance to cytotoxic nucleoside analoguesL Jordheim, C M Galmarini, C Dumontet
Current Cancer Drug Targets|January 29, 2008
Tubulin folding pathways: implication in the regulation of microtubule dynamicsA Beghin, C M Galmarini, C Dumontet
Oncology Research|January 1, 1996
Methionine dependence of tumor cells: programmed cell survival?C Dumontet, A M Roch, G Quash
Cancer Immunology, Immunotherapy : CII|May 1, 1994
Inhibition of immune cell proliferation and cytokine production by lipoprotein-bound gangliosidesC Dumontet, A Rebbaa, J Bienvenu, et al.
Leukemia|June 22, 2001
Nucleoside analogues: mechanisms of drug resistance and reversal strategiesC M Galmarini, J R Mackey, C Dumontet
Anti-Cancer Agents in Medicinal Chemistry|June 10, 2008
Monoclonal antibodies in clinical oncologyS Dalle, C Thieblemont, L Thomas, et al.
Chest|December 1, 1996
Early diagnosis of ventilator-associated pneumonia. Is it possible to define a cutoff value of infected cells in BAL fluid?B Allaouchiche, H Jaumain, C Dumontet, et al.
Pageof 11

Showing results (11-20 of 106) with videos related to

Sort By:
Pageof 11
Clinical and Experimental Rheumatology|August 19, 2000
Giant cell arteritis and polymyalgia rheumatica: role of viral infectionsP Duhaut, S Bosshard, C Dumontet
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
Potential interactions between antitubulin agents and temperature: implications for modulation of multidrug resistanceC Dumontet, F Bodin, Y Michal
Cancer Gene Therapy|April 4, 2009
Development of gene therapy in association with clinically used cytotoxic deoxynucleoside analoguesC Hébrard, C Dumontet, L P Jordheim
Current Drug Targets|July 18, 2003
Drug resistance to cytotoxic nucleoside analoguesL Jordheim, C M Galmarini, C Dumontet
Current Cancer Drug Targets|January 29, 2008
Tubulin folding pathways: implication in the regulation of microtubule dynamicsA Beghin, C M Galmarini, C Dumontet
Oncology Research|January 1, 1996
Methionine dependence of tumor cells: programmed cell survival?C Dumontet, A M Roch, G Quash
Cancer Immunology, Immunotherapy : CII|May 1, 1994
Inhibition of immune cell proliferation and cytokine production by lipoprotein-bound gangliosidesC Dumontet, A Rebbaa, J Bienvenu, et al.
Leukemia|June 22, 2001
Nucleoside analogues: mechanisms of drug resistance and reversal strategiesC M Galmarini, J R Mackey, C Dumontet
Anti-Cancer Agents in Medicinal Chemistry|June 10, 2008
Monoclonal antibodies in clinical oncologyS Dalle, C Thieblemont, L Thomas, et al.
Chest|December 1, 1996
Early diagnosis of ventilator-associated pneumonia. Is it possible to define a cutoff value of infected cells in BAL fluid?B Allaouchiche, H Jaumain, C Dumontet, et al.
Pageof 11